CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Arcus Biosciences, Inc. - RCUS CFD

    15.73
    2.96%
    0.18
    Low: 15.73
    High: 16.52
    Market Trading Hours* (UTC) Opens on Wednesday at 13:30

    Mon - Fri: 13:30 - 20:00

    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    Trading сonditions
    Spread 0.18
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026179 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026179%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003957 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003957%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Key Stats
    Prev. Close* 16.21
    Open* 15.85
    1-Year Change* -9.38%
    Day's Range* 15.73 - 16.52
    52 wk Range 16.74-48.80
    Average Volume (10 days) 702.05K
    Average Volume (3 months) 14.68M
    Market Cap 1.97B
    P/E Ratio 75.24
    Shares Outstanding 72.41M
    Revenue 432.84M
    EPS 0.36
    Dividend (Yield %) N/A
    Beta 0.61
    Next Earnings Date Feb 21, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Apr 15, 2024 16.21 -0.12 -0.73% 16.33 16.52 15.98
    Apr 12, 2024 16.45 -0.47 -2.78% 16.92 17.42 16.09
    Apr 11, 2024 17.24 0.73 4.42% 16.51 17.32 16.51
    Apr 10, 2024 16.67 -0.04 -0.24% 16.71 16.98 16.45
    Apr 9, 2024 17.38 0.79 4.76% 16.59 17.57 16.59
    Apr 8, 2024 16.91 -0.22 -1.28% 17.13 17.25 16.59
    Apr 5, 2024 17.25 0.41 2.43% 16.84 17.28 16.47
    Apr 4, 2024 17.11 -0.48 -2.73% 17.59 17.99 17.10
    Apr 3, 2024 17.62 0.27 1.56% 17.35 17.78 16.90
    Apr 2, 2024 17.67 -0.25 -1.40% 17.92 18.21 17.45
    Apr 1, 2024 18.42 -0.24 -1.29% 18.66 18.75 18.09
    Mar 28, 2024 18.79 0.81 4.51% 17.98 19.06 17.94
    Mar 27, 2024 18.17 1.59 9.59% 16.58 18.48 16.49
    Mar 26, 2024 16.60 0.14 0.85% 16.46 16.64 16.20
    Mar 25, 2024 16.42 0.18 1.11% 16.24 16.53 16.00
    Mar 22, 2024 16.31 -0.71 -4.17% 17.02 17.02 16.28
    Mar 21, 2024 17.11 -0.20 -1.16% 17.31 17.91 17.10
    Mar 20, 2024 17.37 0.34 2.00% 17.03 17.61 16.84
    Mar 19, 2024 17.23 0.35 2.07% 16.88 17.60 16.86
    Mar 18, 2024 17.16 -1.49 -7.99% 18.65 18.65 17.07

    Arcus Biosciences, Inc. Events

    Time (UTC) Country Event
    No events scheduled
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 112 382.882 77.517 15 8.353
    Revenue 112 382.882 77.517 15 8.353
    Total Operating Expense 392 328.634 201.752 103.709 63.212
    Selling/General/Admin. Expenses, Total 104 72.286 42.404 25.228 13.566
    Research & Development 288 256.348 159.348 78.481 49.646
    Operating Income -280 54.248 -124.235 -88.709 -54.859
    Interest Income (Expense), Net Non-Operating 16 0.657 1.377 3.999 5.265
    Net Income Before Taxes -266 54.645 -122.858 -84.71 -49.594
    Net Income After Taxes -267 52.83 -122.858 -84.71 -49.594
    Net Income Before Extra. Items -267 52.83 -122.858 -84.71 -49.594
    Net Income -267 52.83 -122.858 -84.71 -49.594
    Income Available to Common Excl. Extra. Items -267 52.83 -122.858 -84.71 -49.594
    Income Available to Common Incl. Extra. Items -267 52.83 -122.858 -84.71 -49.594
    Diluted Net Income -267 52.83 -122.858 -84.71 -49.594
    Diluted Weighted Average Shares 72 73.9663 54.7871 43.826 34.6182
    Diluted EPS Excluding Extraordinary Items -3.70833 0.71424 -2.24246 -1.93287 -1.4326
    Diluted Normalized EPS -3.70833 0.71424 -2.24246 -1.93287 -1.4326
    Other, Net -2 -0.26
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 29 25 33.655 33.581 26.759
    Revenue 29 25 33.655 33.581 26.759
    Total Operating Expense 112 111 108.096 102.978 95.741
    Selling/General/Admin. Expenses, Total 28 30 27.896 26.294 25.836
    Research & Development 84 81 80.2 76.684 69.905
    Operating Income -83 -86 -74.441 -69.397 -68.982
    Interest Income (Expense), Net Non-Operating 9 9 7.544 5.013 2.861
    Other, Net 0 -1 -0.563 -0.535 -0.511
    Net Income Before Taxes -74 -78 -67.46 -64.919 -66.632
    Net Income After Taxes -75 -80 -67.456 -64.919 -66.632
    Net Income Before Extra. Items -75 -80 -67.456 -64.919 -66.632
    Net Income -75 -80 -67.456 -64.919 -66.632
    Income Available to Common Excl. Extra. Items -75 -80 -67.456 -64.919 -66.632
    Income Available to Common Incl. Extra. Items -75 -80 -67.456 -64.919 -66.632
    Diluted Net Income -75 -80 -67.456 -64.919 -66.632
    Diluted Weighted Average Shares 73.2 73 72.7433 72.2363 71.8142
    Diluted EPS Excluding Extraordinary Items -1.02459 -1.09589 -0.92732 -0.8987 -0.92784
    Diluted Normalized EPS -1.02459 -1.09589 -0.92732 -0.8987 -0.92784
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 1067 1261.75 735.815 192.705 258.948
    Cash and Short Term Investments 1009 499.308 728.646 188.27 256.544
    Cash & Equivalents 206 147.914 173.415 57.937 71.064
    Short Term Investments 803 351.394 555.231 130.333 185.48
    Total Receivables, Net 39 746.822 1.698 0.132 0.083
    Prepaid Expenses 19 15.62 5.471 4.303 2.321
    Total Assets 1345 1591.9 772.292 203.11 274.925
    Property/Plant/Equipment, Total - Net 135 137.423 23.588 9.33 11.107
    Property/Plant/Equipment, Total - Gross 158 155.151 37.876 20.551 18.75
    Accumulated Depreciation, Total -23 -17.728 -14.288 -11.221 -7.643
    Long Term Investments 129 181.99 6.44 0 4.383
    Other Long Term Assets, Total 14 10.735 6.449 1.075 0.487
    Total Current Liabilities 193 166.084 121.669 22.706 16.935
    Accounts Payable 20 10.261 15.682 4.704 3.102
    Accrued Expenses 76 51.953 30.717 9.522 6.023
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 97 103.87 75.27 8.48 7.81
    Total Liabilities 688 750.448 269.988 39.268 39.983
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 495 584.364 148.319 16.562 23.048
    Total Equity 657 841.45 502.304 163.842 234.942
    Preferred Stock - Non Redeemable, Net 0 0 0
    Common Stock 1206 0.007 0.006 0.004 0.004
    Additional Paid-In Capital 1118.06 830.438 369.1 357.873
    Retained Earnings (Accumulated Deficit) -542 -275.354 -328.184 -205.326 -122.828
    Other Equity, Total -7 -1.261 0.044 0.064 -0.107
    Total Liabilities & Shareholders’ Equity 1345 1591.9 772.292 203.11 274.925
    Total Common Shares Outstanding 72.9 70.7718 65.1147 45.925 44.5379
    Redeemable Preferred Stock 0
    Accounts Receivable - Trade, Net 39 746.822 1.698 0.132
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 882 986 1015 1067 1101.12
    Cash and Short Term Investments 799 930 954 1009 1048.78
    Cash & Equivalents 184 230 238 206 217.647
    Short Term Investments 615 700 716 803 831.135
    Total Receivables, Net 56 37 36 39 30.709
    Accounts Receivable - Trade, Net 56 37 36 39 30.709
    Prepaid Expenses 27 19 25 19 21.625
    Total Assets 1191 1220 1254 1345 1393.82
    Property/Plant/Equipment, Total - Net 50 45 37 135 135.965
    Long Term Investments 151 80 90 129 143.138
    Other Long Term Assets, Total 108 109 112 14 13.603
    Total Current Liabilities 200 180 179 193 177.176
    Accounts Payable 17 12 28 20 10.546
    Accrued Expenses 72 55 49 76 60.337
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 111 113 102 97 106.293
    Total Liabilities 671 654 654 688 695.121
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 471 474 475 495 517.945
    Total Equity 520 566 600 657 698.701
    Common Stock 1291 1267 1226 1206 0.007
    Additional Paid-In Capital 1183.39
    Retained Earnings (Accumulated Deficit) -768 -697 -622 -542 -474.898
    Other Equity, Total -3 -4 -4 -7 -9.801
    Total Liabilities & Shareholders’ Equity 1191 1220 1254 1345 1393.82
    Total Common Shares Outstanding 74.8 74.5 73.1 72.9 72.3524
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -267 52.83 -122.858 -84.71 -49.594
    Cash From Operating Activities 438 -256.171 111.17 -73.462 -42.996
    Cash From Operating Activities 6 3.843 3.149 3.578 3.664
    Non-Cash Items 76 62.774 22.821 7.545 1.602
    Changes in Working Capital 623 -375.618 208.058 0.125 1.332
    Cash From Investing Activities -413 -3.868 -434.367 59.212 -113.44
    Capital Expenditures -6 -26.078 -3.055 -1.925 -3.743
    Other Investing Cash Flow Items, Total -407 22.21 -431.312 61.137 -109.697
    Cash From Financing Activities 33 237.34 438.675 1.123 129.074
    Financing Cash Flow Items 10 5 0 -0.135
    Issuance (Retirement) of Stock, Net 23 232.34 438.675 1.123 129.209
    Net Change in Cash 58 -22.699 115.478 -13.127 -27.362
    Cash Taxes Paid -3
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -80 -267 -199.544 -134.625 -67.993
    Cash From Operating Activities -98 438 507.739 588.698 654.001
    Cash From Operating Activities 2 6 4.522 2.962 1.457
    Non-Cash Items 17 76 59.226 42 23.078
    Changes in Working Capital -37 623 643.535 678.361 697.459
    Cash From Investing Activities 129 -413 -459.811 -483.257 -268.06
    Capital Expenditures -3 -6 -5.62 -4.302 -2.788
    Other Investing Cash Flow Items, Total 132 -407 -454.191 -478.955 -265.272
    Cash From Financing Activities 1 33 21.805 19.274 14.928
    Financing Cash Flow Items 0 10 5 5 5
    Issuance (Retirement) of Stock, Net 1 23 16.805 14.274 9.928
    Net Change in Cash 32 58 69.733 124.715 400.869
    Cash Taxes Paid -3 2.743

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Arcus Biosciences, Inc. Company profile

    Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer therapies in the United States. The company''s product pipeline includes, AB928, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 monoclonal antibody that is in Phase Ib clinical trial for monotherapy. It is also developing AB154, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab and AB928; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. Arcus Biosciences, Inc. has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics (Cayman) Inc.; and co-development and co-commercialization partnership with Gilead Sciences, Inc. for the development of cancer immunotherapies. The company was founded in 2015 and is based in Hayward, California.
    Industry: Biotechnology & Medical Research (NEC)

    3928 Point Eden Way
    HAYWARD
    CALIFORNIA 94545-3719
    US

    Income Statement

    • Annual
    • Quarterly

    News

    US Earnings Season : JP Morgan, Citigroup, Wells Fargo

    The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

    16:03, 11 April 2024

    Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

    The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

    09:22, 11 April 2024

    US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

    US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

    15:11, 9 April 2024

    How escalating geopolitical tensions are impacting oil markets

    The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

    13:34, 4 April 2024

    A way forward: a roundup of recent central bank decisions

    Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

    12:47, 22 March 2024

    Bank of Japan Preview: will the BOJ end negative interest rates?

    The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

    08:44, 18 March 2024

    Higher CPI leaves traders unfazed as US equities continue to build momentum

    The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

    12:42, 15 March 2024

    People also watch

    BTC/USD

    62,916.10 Price
    -0.470% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 106.00

    XRP/USD

    0.50 Price
    +0.130% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01168

    US100

    17,724.30 Price
    +0.070% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 21:00 (UTC)
    Spread 1.8

    ETH/USD

    3,066.45 Price
    -0.480% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 6.00

    Still looking for a broker you can trust?

    Join the 610,000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading